About US
Contact us
-
Eisai and Biogen partner to develop new treatments for Alzheimer'sJapanese pharmaceutical firm Eisai has entered into a collaboration with US-based Biogen Idec for the development and commercialisation of Eisai's two clinical candidates E2609 and BAN2401 for treatin2014/3/10
-
Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's diseaseUS-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donep2014/3/7
-
AstraZeneca obtains FDA approval for Bydureon Pen to treat type 2 diabetesAstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bydureon Pen (exenatide extended-release for injectable suspension) 2mg as an adjunct to diet and exercise to i2014/3/7
-
Bayer seeks Japanese approval for VEGF Trap-Eye to treat diabetic macular edemaBayer HealthCare's Japanese subsidiary Bayer Yakuhin has submitted a marketing authorisation application to Japan's Ministry of Health, Labour and Welfare (MHLW) for vascular endothelial growth factor2014/3/6
-
Eisai and Biogen Idec Collaborate to Develop and Commercial​ize Alzheimer'​s Disease TreatmentsEisai Co., Ltd and Biogen Idechave entered into a collaboration to develop and commercialise two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. The agreement also prov2014/3/6
-
GW Pharma obtains FDA orphan status for Epidiolex for treatment of Lennox syndromeBritish biopharmaceutical firm GW Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its Epidiolex as a treatment for Lennox-Gastaut syndrome (LGS)2014/3/5
-
Ignyta files IND application with FDA for tumour drug RXDX-101Ignyta has filed an investigational new drug application (IND) with the US Food and Drug Administration (FDA) for its RXDX-101, an oral tyrosine kinase inhibitor targeting solid tumour indications. T2014/3/5
-
Cobra Biologics and BioCancell Announce Agreement to Manufactur​e Promising Cancer Therapy DrugCobra Biologics, a leading contract manufacturer of clinical and commercial-scale biologics and pharmaceuticals, and targeted cancer therapy company BioCancell have announced an agreement to manufactu2014/3/4
-
The Medicines Company's MMA for oritavancin accepted by EMA for reviewThe European Medicines Agency (EMA) has accepted The Medicines Company's (MDCO) investigational intravenous antibiotic, oritavancin, for review of a marketing authorisation application (MAA). Oritava2014/3/4
-
Galderma's Mirvaso receives European approval for treatment of RosaceaThe European Commission (EC) has granted marketing authorisation in Europe for Switzerland-based pharmaceutical firm Galderma's Mirvaso (brimonidine) 3mg/g gel for the treatment of facial redness, als2014/3/3